SCHEMBL8424729

SCHEMBL8424729

CCc1ccc2oc(-c3ccc(OC)c(OC)c3)c(O)c(=O)c2c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.73
KDM4E B2RXH2 4/20 0.73
CYP3A4 P08684 4/20 0.73
CASP1 P29466 4/20 0.73
CASP7 P55210 4/20 0.73
MEN1 O00255 3/20 0.73
ALDH1A1 P00352 3/20 0.73
KMT2A Q03164 3/20 0.73
TP53 P04637 8/20 0.69
LMNA P02545 3/20 0.69
HPGD P15428 2/20 0.69
HSD17B10 Q99714 2/20 0.69
ABCB1 P08183 3/20 0.64
ABCG2 Q9UNQ0 4/20 0.63
RXFP1 Q9HBX9 4/20 0.58
POLB P06746 2/20 0.57
CSNK2A2 P19784 3/20 0.56
CSNK2B P67870 3/20 0.56
CSNK2A1 P68400 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8424959 0.92 CSNK2A2 (0.67) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL1421411 0.85 MAPT (0.65) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL30667444 0.84 MAPT (1.00) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL4648874 0.84 ABCG2 (0.82) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL5138212 0.84 MAPT (1.00) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL7609382 0.84 MAPT (0.70) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL25235022 0.84 ABCB1 (0.79) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL30397364 0.84 ABCB1 (0.79) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL30667420 0.83 MAPT (0.76) MAPTKDM4ECYP3A4CASP1CASP7
SCHEMBL1422017 0.83 MAPT (0.76) MAPTKDM4ECYP3A4CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 EP disclosed